ARQT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Arcutis presents ZORYVE (roflumilast) data and real-world research on topical corticosteroids at EADV and Fall ClinicalOct 9, 2026
- FDA accepted Arcutis' supplemental NDA for ZORYVE cream 0.05% to treat mild to moderate atopic dermatitis in infants as young as 3 monthsJul 8, 2026
- FDA approved Arcutis' ZORYVE cream 0.3% for plaque psoriasis in children aged two years and olderJul 1, 2026
- Arcutis submitted a supplemental NDA to the FDA to expand ZORYVE cream use for atopic dermatitis in infants as young as 3 monthsApr 27, 2026
- Arcutis published long-term safety and efficacy data for ZORYVE cream 0.05% in children aged 2–5 with mild-to-moderate atopic dermatitisMar 11, 2026